PEN Penumbra, Inc.

319.12USD-0.28%Mkt Cap: 12.58B USDP/E: 80.38

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombect…

Institutional holders20 on file

Key Statistics

Company
Market Cap12.58B USD
Enterprise Value12.15B USD
Revenue (TTM)1.56B USD
Gross Profit942.44M USD
Net Income (TTM)177.69M USD
Revenue/Share39.70 USD
Last Price319.12 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4.7K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)80.38
P/E (Forward)53.09
PEG3.61
EV/EBITDA58.08
EV/Revenue7.79
P/S8.06
P/B7.94
EPS (TTM)3.97 USD
EPS (Forward)6.01 USD
52W Range
276.0150% of range362.41
52W High362.41 USD
52W Low276.01 USD
Profitability
Gross Margin67.14%
Oper. Margin12.13%
EBITDA Margin13.41%
Profit Margin12.66%
ROE12.45%
ROA9.73%
ROIC14.87%
ROCE11.52%
Growth
Revenue Growth15.60%
Earnings Growth-8.50%
Cash Flow & Leverage
Operating CF238.66M USD
CapEx (TTM)63.73M USD
FCF Margin10.64%
FCF Yield1.32%
Net Debt-464.22M USD
Net Debt/EBITDA-2.22
Net Debt/FCF-2.80
Balance Sheet
Debt/Equity0.15
Current Ratio5.89
Quick Ratio3.72
Book Value/Sh40.18 USD
Cash/Share17.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)362.54 USD
Upside (mean)+13.6%
Target Range320.00 USD – 374.00 USD
320.00+13.6% to mean374.00
# Analysts13
Ownership
Shares Out.39.41M
Float38.30M
Insiders2.97%
Institutions92.25%
Short Interest
Short Ratio6.1d
Short % Float7.01%
Short % Out.6.10%
Shares Short2.40M
Short (prev mo.)2.25M
Technical
SMA 50320.13 (-0.3%)
SMA 200325.16 (-1.9%)
Beta0.69
S&P 52W Chg12.00%
Avg Vol (30d)349.63K
Avg Vol (10d)274.38K
Technical Indicators
RSI (14)45.1
MACD-0.2889
MACD Signal-0.0375
MACD Hist.-0.2514
BB Upper324.36 USD
BB Middle320.94 USD
BB Lower317.52 USD
BB Width2.13%
ATR (14)2.153 USD
Vol Ratio (20d)0.55x

About Penumbra (NYSE: PEN)

›

Penumbra (NYSE: PEN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4,700 employees.

The shares were at 319.12 USD on 20 November 2026, up 14.6% over 52 weeks. Its 52-week range is 276.01 USD to 362.41 USD: the price is 11.9% below the high and 15.6% above the low.

At a market capitalisation of 12.58B USD, it trades at 80.4 times trailing earnings and 53.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 24.9, a premium of 223% for PEN.

Penumbra reports return on equity of 12.4%, an operating margin of 12.1% and revenue up 15.6% year over year.

It holds more cash than debt, a net cash position of 464.22M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 362.54 USD is 13.6% above the current price. The next earnings report is expected on 24 February 2027.